🚨 New #CardioOnc Webinar | 'Cardio-Oncology Survivorship Workshop: From Guidelines to Practice - MODULE 2 - During Treatment: Managing Toxicity Without Derailing Care'.
⏰ 12:30 GMT | 07:30 EST
📅 Tuesday 10 November
Don’t miss out on this discussion with Dr Thiwanka t and Dr Husam Abdel-Qadir.
Register now 👉 radcliffecardiology.com/webinars/cardi…
This webinar is supported by IC-OS.
@ICOSociety
⏰ 12:30 GMT | 07:30 EST
📅 Tuesday 10 November
Don’t miss out on this discussion with Dr Thiwanka t and Dr Husam Abdel-Qadir.
Register now 👉 radcliffecardiology.com/webinars/cardi…
This webinar is supported by IC-OS.
@ICOSociety
0
0
0
68
📚 New #CFRJournal Article: "Safety and Usability of Robot-Assisted Echocardiographic Examination"
📚 Just Published!
🔓Access it here 👉 ow.ly/towv106I0mH
#CVImaging #MedEd
📚 Just Published!
🔓Access it here 👉 ow.ly/towv106I0mH
#CVImaging #MedEd
0
0
1
135
🤖 What can #AI reveal from a cardiac CT beyond stenosis?
📺 @WomenAs1 #CLIMB2026 presents AI in Cardiac CT with Dr Jeffrey Bander. Watch now 👉
🫀 Explore AI-powered plaque analysis
📊 See how CT-derived FFR adds functional insight
🔍 Discover the future of AI-supported s://t.co/N6ONzwdTXT
#CardiacCT #CardioEd #WomenInCardiology #CardiacImaging
📺 @WomenAs1 #CLIMB2026 presents AI in Cardiac CT with Dr Jeffrey Bander. Watch now 👉
🫀 Explore AI-powered plaque analysis
📊 See how CT-derived FFR adds functional insight
🔍 Discover the future of AI-supported s://t.co/N6ONzwdTXT
#CardiacCT #CardioEd #WomenInCardiology #CardiacImaging
0
1
2
210
Even with LDL-C well controlled, many patients remain at cardiovascular risk.
Ahead of AHA 2026, this three-part programme provides a focused spotlight on the latest evidence surrounding EPA and its evolving role in cardiovascular risk reduction, with a particular focus on the ongress 2026. Through expert-led presentations and discussion, Prof Chris Packard and Prof Philippe Gabriel Steg explore the implications of these findings for clinical decision-making in patients with elevated triglycerides and residual cardiovascular risk.
Watch on demand: radc.life/QiJ8cSCn
#ESC2026 #Cardiology #LipidManagement #CardiovascularRisk #MedicalEducation
This programme is supported by an unrestricted educational grant from Amarin.
Ahead of AHA 2026, this three-part programme provides a focused spotlight on the latest evidence surrounding EPA and its evolving role in cardiovascular risk reduction, with a particular focus on the ongress 2026. Through expert-led presentations and discussion, Prof Chris Packard and Prof Philippe Gabriel Steg explore the implications of these findings for clinical decision-making in patients with elevated triglycerides and residual cardiovascular risk.
Watch on demand: radc.life/QiJ8cSCn
#ESC2026 #Cardiology #LipidManagement #CardiovascularRisk #MedicalEducation
This programme is supported by an unrestricted educational grant from Amarin.
0
0
0
132
Angiography waits from months to weeks. Reduced costs and improved cath lab efficiency.
Dr Peter Haworth shares how QA Portsmouth is using #Heartflow FFRct to streamline investigations and inform clinical decisions.
🔗 Watch here: ow.ly/cvm85101Zu9
This series is
#FFRct #CardiacCT #MedTech #Cardiology #NHSInnovation #NHSTrusts
Dr Peter Haworth shares how QA Portsmouth is using #Heartflow FFRct to streamline investigations and inform clinical decisions.
🔗 Watch here: ow.ly/cvm85101Zu9
This series is
#FFRct #CardiacCT #MedTech #Cardiology #NHSInnovation #NHSTrusts
0
0
1
161
🔴 Expert-led #CardioOnc webinar happening TODAY titled 'Is Cancer Still a Contraindication? Advanced Cardiac Procedures in Oncology Patients' 👉 ow.ly/m84y5103JB2
⏰ 14:00 GMT | 9:00 EST
Don’t miss out on this discussion with Dr Joe Carver, Dr Daniel Lenihan, Dr Jose Daniel Hwang.
See you there 👋
This webinar is supported by IC-OS.
@ICOSociety
⏰ 14:00 GMT | 9:00 EST
Don’t miss out on this discussion with Dr Joe Carver, Dr Daniel Lenihan, Dr Jose Daniel Hwang.
See you there 👋
This webinar is supported by IC-OS.
@ICOSociety
0
0
1
191
📚 New #ECRJournal Article: "Letter to Editor Regarding TAVI Management"
📚 Just Published!
🔓Access it here 👉 ow.ly/SGpj106HWhm
#MedEd #CardioEd
📚 Just Published!
🔓Access it here 👉 ow.ly/SGpj106HWhm
#MedEd #CardioEd
0
0
0
174
The #AHA2026 late-breaking results are only the beginning.
At #ScientificSessions26, Dr @hvanspall returns to host the Late-Breaking Discussions:
🩺 OPTIMAL → How low should BP go?
🧬 Lp(a)HORIZON → What can the full data teach us about Lp(a) lowering?
❤️ RACE-CARS → How can be improved?
🔥 ZEUS → What can we learn from targeting IL-6-mediated inflammation?
With Prof @OtavioBerwanger, Dr Karla Santo, Dr @GiseleSampaioS, Dr Steven Nissen, Prof Christopher Granger and Dr Paul Ridker
Coming soon
#ScientificSessions26 #LateBreakingScience #CardioTwitter
At #ScientificSessions26, Dr @hvanspall returns to host the Late-Breaking Discussions:
🩺 OPTIMAL → How low should BP go?
🧬 Lp(a)HORIZON → What can the full data teach us about Lp(a) lowering?
❤️ RACE-CARS → How can be improved?
🔥 ZEUS → What can we learn from targeting IL-6-mediated inflammation?
With Prof @OtavioBerwanger, Dr Karla Santo, Dr @GiseleSampaioS, Dr Steven Nissen, Prof Christopher Granger and Dr Paul Ridker
Coming soon
#ScientificSessions26 #LateBreakingScience #CardioTwitter
0
5
5
456
🚨 New #CardioOnc Webinar | 'Journal Club: PRADA II' this Thursday.
⏰ 14:00 GMT | 09:00 EST
Don’t miss out on this discussion with Dr Joe Carver, Dr Daniel Lenihan, Dr Jose Álvarez-Cardona and Dr Daniel Hwang.
Register now👉 ow.ly/lHXS5103JtA
This webinar is supported by IC-OS.
@ICOSociety
⏰ 14:00 GMT | 09:00 EST
Don’t miss out on this discussion with Dr Joe Carver, Dr Daniel Lenihan, Dr Jose Álvarez-Cardona and Dr Daniel Hwang.
Register now👉 ow.ly/lHXS5103JtA
This webinar is supported by IC-OS.
@ICOSociety
0
1
3
313
📚 New #ECRJournal Article: "Antiplatelet Strategies After PCI: Risk–Benefit Network Meta-Analysis"
📚 Just Published!
🔓Access it here 👉 ow.ly/HJJ7106HPx8
#MedEd #CardioEd #Anticoagulation
📚 Just Published!
🔓Access it here 👉 ow.ly/HJJ7106HPx8
#MedEd #CardioEd #Anticoagulation
0
0
1
209
⚖️ Obesity is a key driver of cardiovascular-kidney-metabolic disease, but effective treatment options have never been greater.
📺 @WomenAs1 #CLIMB2026 presents Treatment of Obesity: Lifestyle, Medications and Bariatric Surgery with Dr Alison L Bailey.
🏃 Lifestyle besity medications
⚕️Bariatric surgery
🫀 Improving CKM outcomes
Stay tuned for more from the Cardiorenal Metabolic Health track!
🔗 ow.ly/tTqY5101EOz
#Obesity #CKM #CardioEd #PreventiveCardiology #WomenInCardiology
📺 @WomenAs1 #CLIMB2026 presents Treatment of Obesity: Lifestyle, Medications and Bariatric Surgery with Dr Alison L Bailey.
🏃 Lifestyle besity medications
⚕️Bariatric surgery
🫀 Improving CKM outcomes
Stay tuned for more from the Cardiorenal Metabolic Health track!
🔗 ow.ly/tTqY5101EOz
#Obesity #CKM #CardioEd #PreventiveCardiology #WomenInCardiology
0
1
1
275
📚 New #CFRJournal Article: "Foreword: Sleep-disordered Breathing in Heart Failure"
📚 Just Published!
🔓Access it here 👉 ow.ly/6xSo106HKk7
@HFA_President #HeartFailure #CardioTwitter #MedEd
📚 Just Published!
🔓Access it here 👉 ow.ly/6xSo106HKk7
@HFA_President #HeartFailure #CardioTwitter #MedEd
0
0
1
275
Radcliffe Cardiology retweeted
🔴 #TCT2026 | PROGRESS
Dr Nadira Hamid talks to Prof @PPibarot about PROGRESS in moderate AS + ≥1 at-risk feature:
📉 Death/#HF event: 16.7% vs 23.9%
🏥 HF hospitalisation: 7.4% vs 14.9%
“Moderate is not a benign disease.”
Prof Philippe Pibarot
🎥 Watch: radc.life/LSeyZj1P
ithNadira #PROGRESS #TAVR #AorticStenosis #CardioTwitter
Dr Nadira Hamid talks to Prof @PPibarot about PROGRESS in moderate AS + ≥1 at-risk feature:
📉 Death/#HF event: 16.7% vs 23.9%
🏥 HF hospitalisation: 7.4% vs 14.9%
“Moderate is not a benign disease.”
Prof Philippe Pibarot
🎥 Watch: radc.life/LSeyZj1P
ithNadira #PROGRESS #TAVR #AorticStenosis #CardioTwitter
0
2
1
214
📚 New #USCJournal Article: "ANOCA: Diagnostic Evaluation and Endotype-guided Management"
📚 Just Published!
🔓Access it here 👉 ow.ly/l6Kn106HHjQ
@CardioNerds #CVImaging #MedEd #CardioEd
📚 Just Published!
🔓Access it here 👉 ow.ly/l6Kn106HHjQ
@CardioNerds #CVImaging #MedEd #CardioEd
0
3
4
790
🫀 TEER or TTVR when both are technically possible?
At #TCT2026, @drnvanmieghem and Dr Azeem Latib examine:
▪ Patient selection
▪ Residual TR
▪ RV function
▪ Quality of life vs harder outcomes ▪ Repair vs replacement, head-to-head?
Watch discussion here: radc.life/BSDkxTSJ
#TricuspidRegurgitation #StructuralHeart #TEER #TTVR #HeartValveDisease #InterventionalCardiology #CardioTwitter
At #TCT2026, @drnvanmieghem and Dr Azeem Latib examine:
▪ Patient selection
▪ Residual TR
▪ RV function
▪ Quality of life vs harder outcomes ▪ Repair vs replacement, head-to-head?
Watch discussion here: radc.life/BSDkxTSJ
#TricuspidRegurgitation #StructuralHeart #TEER #TTVR #HeartValveDisease #InterventionalCardiology #CardioTwitter
0
1
3
690
TRANSFORM II at #TCT2026
1,842 patients | 53 sites
📊 TLF: 2.1% SCB vs 2.4% EES
✓ Non-inferiority met
🔹 Bailout stenting: 7.6%
Bernardo Cortese:
“Only after five years will we know what is best in this lesion setting.”
What do these data add to the de novo DCB discussion?
radc.life/BSDkxTSJ
#TRANSFORMII #DCB #PCI #TCT2026
1,842 patients | 53 sites
📊 TLF: 2.1% SCB vs 2.4% EES
✓ Non-inferiority met
🔹 Bailout stenting: 7.6%
Bernardo Cortese:
“Only after five years will we know what is best in this lesion setting.”
What do these data add to the de novo DCB discussion?
radc.life/BSDkxTSJ
#TRANSFORMII #DCB #PCI #TCT2026
0
1
12
830
P4 at #TCT2026: Can CT guide PCI?
1,100 patients, CCTA- vs IVUS-guided PCI:
• 1-year TVF: 4.1% vs 4.6%
• Non-inferiority achieved
• 17 min shorter procedural time
• 20 mL less contrast
Dr Carlos Collet in conversation with @drnvanmieghem
“Before you put your foot on the what you’re going to see.”
▶️ Watch the discussion: radc.life/dzG1ZyXS
#TCT2026 #P4Trial #PCI #CCTA #IVUS #CoronaryCT #InterventionalCardiology #Cardiology #CardioTwitter
1,100 patients, CCTA- vs IVUS-guided PCI:
• 1-year TVF: 4.1% vs 4.6%
• Non-inferiority achieved
• 17 min shorter procedural time
• 20 mL less contrast
Dr Carlos Collet in conversation with @drnvanmieghem
“Before you put your foot on the what you’re going to see.”
▶️ Watch the discussion: radc.life/dzG1ZyXS
#TCT2026 #P4Trial #PCI #CCTA #IVUS #CoronaryCT #InterventionalCardiology #Cardiology #CardioTwitter
2
12
24
1,774
Should treatment goals in severe hypertriglyceridaemia extend beyond lowering triglycerides?
Ahead of AHA 2026, review the latest evidence from the SHASTA-3 and SHASTA-4 studies and hear expert perspectives on apoC-III inhibition and pancreatitis prevention from Dr Robert chos.
Watch here 🔗radc.life/ZGfm6Y51
This programme is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.
#ESC2026 #sHTG #MedEd
Ahead of AHA 2026, review the latest evidence from the SHASTA-3 and SHASTA-4 studies and hear expert perspectives on apoC-III inhibition and pancreatitis prevention from Dr Robert chos.
Watch here 🔗radc.life/ZGfm6Y51
This programme is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.
#ESC2026 #sHTG #MedEd
0
0
1
287
⚖️ Obesity is a key driver of cardiovascular-kidney-metabolic (CKM) disease.
📺 @WomenAs1 #CLIMB2026 presents Obesity and the Cardiovascular-Kidney-Metabolic Continuum with Dr Harriette Van Spall.
✅ Understanding CKM stagin
✅ Better measures of cardiometabolic risk
✅ Kidney egies
✅ Practical prevention approaches
🔗 Watch here: ow.ly/M2hU5101EKP
#CKM #CardiorenalHealth #Obesity #CardioEd #WomenInCardiology
📺 @WomenAs1 #CLIMB2026 presents Obesity and the Cardiovascular-Kidney-Metabolic Continuum with Dr Harriette Van Spall.
✅ Understanding CKM stagin
✅ Better measures of cardiometabolic risk
✅ Kidney egies
✅ Practical prevention approaches
🔗 Watch here: ow.ly/M2hU5101EKP
#CKM #CardiorenalHealth #Obesity #CardioEd #WomenInCardiology
0
1
2
384
EPA, fibrates and residual cardiovascular risk: what does the evidence tell us?
Prof Philippe Gabriel Steg and Dr Samuel Sherratt discuss the data informing current ACC/AHA, ESC and ADA recommendations and the questions that continue to shape clinical practice.
Watch the #ACC26 //t.co/v0EVWYwA7Q
This programme is supported by an unrestricted educational grant from Amarin.
#Cardiology #LipidManagement #CVRiskReduction
Prof Philippe Gabriel Steg and Dr Samuel Sherratt discuss the data informing current ACC/AHA, ESC and ADA recommendations and the questions that continue to shape clinical practice.
Watch the #ACC26 //t.co/v0EVWYwA7Q
This programme is supported by an unrestricted educational grant from Amarin.
#Cardiology #LipidManagement #CVRiskReduction
0
0
0
287